Overview
Phase II Study of Reduced MBF Regimen for Patients Over 50 Years With Myeloid Malignancies
Status:
Recruiting
Recruiting
Trial end date:
2025-01-01
2025-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
In this multiple-center phase II study, we plan to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML over 50 years.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Criteria
Inclusion Criteria:- Age 51-65
- patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or
haplo-identical donors.
- patients with AML in remission, or MDS in any stage, or CMML in any stage
- inform consent provided
Exclusion Criteria:
- patients with abnormal liver (>3N), renal (1.5N) or cardiac function
- patients with active infection